Clinical OMICS

JAN-FEB 2017

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link:

Contents of this Issue


Page 44 of 47 January/February 2017 Clinical OMICs 43 WuXi NextCODE, a Cambridge, MA-based global contract genomics organiza- tion, has announced a partnership with Chicago-based AbbVie, a global research- based biopharmaceutical company and Genomics Medicine Ireland (GMI) to look for ways to cure cancer, neuro- and immunological diseases. Hannes Smarason, COO at WuXi NextCODE, says the partnership will focus on a total of seven applications within the areas of oncology, neuroscience, and immunology. AbbVie is fronting the funding for the project and Genomics Medi- cine Ireland is providing the samples. NextCode will provide the analytics. The trial will last 15 years, with the first part of the trials exclusively belonging to AbbVie. Other parties will be able to participate in the latter half, Smarason said. Ireland is a good location for the study because the Irish population is more homogenous than most other European countries, Smarason said. "It's also not a big place, so it's relatively easy to access the different disciplines," he said. The studies will use 5,000 patients per indication, using information needed their electronic medical records, and in some cases from their wearable devices, combines with sequencing data. The data will then be collated and curated to look for high-impact variance for a starting point in the research, Smarason said. "Genomics is transforming the way we understand some of the world's most devastating diseases and enabling the discovery of new approaches that have the potential to deliver much greater benefit to patients," said Jim Sullivan, vice presi- dent of pharmaceutical discovery at AbbVie. "This alliance is an important part of our research strategy and complements our significant footprint here in Ireland." Daniel Crowley, acting CEO of GMI, said the partnership validates the vision that created Genomics Medicine Ireland. "With AbbVie and WuXi NextCODE we will leverage our deep expertise in life sciences and the unique characteristics of the Irish population to discover critical insights into disease, disease progression, and therapeutic response," he said.—Diana Manos GMI's Dan Crowley, Paul Thurk, Sean Ennis, Maurice Treacy, with Irish Prime Minister Enda Kenny. Conor McCabe (continued from previous page) WuXi NextCODE, AbbVie, and Genomics Medicine Ireland Announce Partnership Cynthia Collins as his successor. Collins comes to HLI from GE Healthcare where she served as the CEO and general man- ager of the company's cell therapy and purification and analysis businesses. Company co-founder Dr. Venter will con- tinue to serve as chairman of the board. "2017 will be a key year for HLI with the launch and expansion of many of our products including oncology, whole genome, HLI Knowledgebase, HLI Search, and the HLI Health Nucleus," said Dr. Venter. "Cindy's combination of innovative business leadership, coupled with commercialization and operations acumen in a variety of life science arenas, is the perfect skillset to bring our vision of high-quality, genomic-powered prod- ucts to the global marketplace." Genospace Merges with Sarah Cannon Genospace, a provider of cloud-based precision medicine software tools, announced a merger agreement under which it will become a wholly owned subsidairy of Sarah Cannon, the global cancer institute of Hospital Corporation of America (HCA). According to Sarah Cannon, the Genospace technology will allow it to use molecular profiling data to more effectively match cancer patients to clinical trials. "Genospace's innovative technol- ogy approach to understanding each patient's cancer directly supports our strategic goal of personalizing care delivery," said Jonathan B. Perlin, M.D., Ph.D., president, clinical services, and chief medical officer at HCA. "By tailoring treatments based on the unique genetic make-up of a patient's cancer, we can more effectively treat the disease." Genospace will retain its Cambridge, MA headquarters, and lead development of a cloud-based system to allow the analysis of disparate data from clinical and laboratory sources across patient populations. n

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - JAN-FEB 2017